The share price of Pro Medicus Limited (ASX: PME) has surged 9% higher in early trade following the announcement of another key contract win in the United States.

The leading health imaging company has reported that its wholly-owned US-based subsidiary Visage Imaging has signed a six-year contract worth A$18 million with Mayo Clinic.

The contract is based on a transaction licensing model and will see Pro Medicus’ Visage 7 technology implemented across Mayo Clinic’s radiology practices. This is the third significant contract win in three months for the company thanks to this increasingly popular technology.

Visage 7 has fast server-side processing technology delivering enterprise diagnostic, clinical, and mobile viewing solutions for healthcare institutions that want to dramatically accelerate and enhance the delivery of radiology services.

CEO Dr Sam Hupert had this to say on the contract win:

“This is a very significant contract for us and further validates our belief that Visage 7 is uniquely positioned to cater for the needs of the most sophisticated and demanding clinical environments. It has the speed and functionality to meet the requirements of a large and diverse group of high-end clinical users as well as the scalability to handle the huge data volumes that a medical enterprise of this size generates.”

I believe this latest contract win is one of many to come in the future. The company’s radiology technology is widely regarded by many in the industry as being best in class. This is helping it gain a lot of traction in the US picture archiving and communication system market which the company has previously estimated to be worth around US$1.7 billion annually.

This bodes well for growth in my opinion and makes Pro Medicus a tempting long-term growth investment, especially considering that it carries zero debt on its books. But because its shares are trading at 152x trailing earnings, I feel it would only be suitable for those with a high risk tolerance.

Investors with a lower tolerance for risk who are looking for exposure to the healthcare industry might want to take a closer look at Ramsay Health Care Limited (ASX: RHC) or ResMed Inc. (CHESS) (ASX: RMD) instead.

Finally, if you're looking for even more ideas for your portfolio then I would highly recommend these three growing blue chip shares. They provide a solid dividend and I believe they can produce share price gains in the months ahead.

Why These 3 Blue Chip Shares Are Set to Soar in 2016

Discover The Motley Fool's Top 3 blue chips for 2016. These 3 'new breed' shares pay fully franked dividends AND offer the prospect of significant capital appreciation. Simply click here to gain access to this comprehensive FREE investment report.

No credit card required!

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.